Trial reportDrug design, development and therapy2026
Combined Use of Etomidate and Propofol Reduce the Duration of Apnea vs Propofol Alone in Patients Undergoing Hysteroscopy: A Randomised Double-Blind Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of respiratory suppression remains high in outpatients receiving intravenous anesthesia for hysteroscopy, presenting a substantial risk to safety. Combined use of etomidate and propofol may reduce apnea duration compared with propofol alone. Objective: To verify the co-primary hypotheses that the Etomidate-propofol combination provides non-inferior sedation efficacy and superior reduction of apnea duration compared with propofol alone. Methods: The double-blind, parallel-group randomized trial was conducted at Renji Hospital, Shanghai, from September 2022 to December 2023. Women aged 18-65 years for elective hysteroscopies under intravenous sedation were included. The exclusion criteria included upper airway abnormalities, severe preoperative cardiac, liver, or kidney diseases, preoperative respiratory insufficiency, high reflux risk, allergy to study drugs, or serious psychological disorders or used psychotropic medications. Patients were randomized to receive either 0.2% etomidate 10mg + 1% propofol 100 mg or 1% propofol 150 mg alone, both in a total volume of 15 mL. All patients were given sufentanil (0.15 µg/kg). Co-primary outcomes were non-inferiority in sedation efficacy with an 7% margin and superiority on apnea duration. Results: A total of 365 subjects were included with combination (n = 182) and propofol alone (n = 183). Patients in both groups were adequately sedated, and the combination was significantly non-inferior to propofol alone. Median apnea duration was significantly shorter in the combined group (73 s) than in the propofol group (116 s, difference, -43 s; P < 0.001). Fewer patients in the combined group required manual ventilation (17% vs 37% for propofol, P < 0.0001). Haemodynamic responses were similar for each approach. Conclusion: The combination of etomidate and propofol provides comparable sedative efficacy to propofol alone during hysteroscopy, while significantly shortening apnea duration induced by intravenous sedatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.